About this item:

101 Views | 109 Downloads

Author Notes:


The authors would like to thank the hematology, critical care medicine, nephrology and transfusion medicine teams at Children’s Healthcare of Atlanta for their assistance with patient care.


Research Funding:

No funding was used to conduct this study.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology

Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease

Show all authors Show less authors


Journal Title:



Volume 105, Number 12


, Pages 2887-2891

Type of Work:

Article | Final Publisher PDF


Despite being the first genetic disease described, sickle cell disease (SCD) continues to afflict patients with immense pain, significant comorbidities and premature death. SCD has only recently benefited from new interventions with L-glutamine (2017), voxelotor (2019) and crizanlizumab (2019) representing the first Food and Drug Administration approved medications for SCD since hydroxyurea in 1997. These interventions have demonstrated some ability to reduce vaso-occlusive pain crisis episodes, improve hemoglobin (HGB), or reduce markers of hemolysis and have largely been used as preventative care measures. While these and additional approaches, such as hematopoietic stem cell transplant and gene therapy, can improve SCD care, many patients with SCD continue to suffer from severe acute SCD complications that can result in organ damage and early death.1,2 Unfortunately, in these situations, supportive care remains the primary approach to alleviate complications. The lack of more targeted approaches in part reflects an incomplete understanding of the pathophysiology and accompanying pharmacological targets that could specifically mitigate acute disease complications. We present a summary of three cases of children with SCD who developed significant acute complications that demonstrate underlying complement-mediated thrombotic microangiopathy (CM-TMA). These cases include a delayed hemolytic transfusion reaction (DHTR), vasoocclusive crisis (VOC) and drug-induced immune hemolytic anemia (DIIHA).

Copyright information:

© 2020 Ferrata Storti Foundation

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/).
Export to EndNote